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Abstract
Background: The loss of AP-2a and increased activity of cAMP-responsive element binding (CREB) protein are two hallmarks
of malignant progression of cutaneous melanoma. However, the molecular mechanism responsible for the loss of AP-2a
during melanoma progression remains unknown.
Methodology/Principal Findings: Herein, we demonstrate that both inhibition of PKA-dependent CREB phosphorylation, as
well as silencing of CREB expression by shRNA, restored AP-2a protein expression in two metastatic melanoma cell lines.
Moreover, rescue of CREB expression in CREB-silenced cell lines downregulates expression of AP-2a. Loss of AP-2a
expression in metastatic melanoma occurs via a dual mechanism involving binding of CREB to the AP-2a promoter and
CREB-induced overexpression of another oncogenic transcription factor, E2F-1. Upregulation of AP-2a expression following
CREB silencing increases endogenous p21
Waf1 and decreases MCAM/MUC18, both known to be downstream target genes of
AP-2a involved in melanoma progression.
Conclusions/Significance: Since AP-2a regulates several genes associated with the metastatic potential of melanoma including c-
KIT, VEGF, PAR-1, MCAM/MUC18, and p21
Waf1, our data identified CREB as a major regulator of the malignant melanoma phenotype.
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Introduction
Malignant melanoma is a highly aggressive disease for which
successful treatment modalities have not been established. A
number of genetic alterations including loss of tumor suppressor
proteins encoded by the INK4a/ARF gene locus, or oncogenic
BRAF mutations, occur early during melanomagenesis [1,2,3].
However, the key event in the progression of melanoma toward a
malignant, locally-invasive and metastatic phenotype is the loss of
the Activator Protein-2a (AP-2a) tumor suppressor protein.
AP-2a is a 52-kD retinoic acid-inducible protein that regulates
gene expression during embryonic morphogenesis and adult cell
differentiation [4,5]. In cancers like melanoma, AP-2a and other
de-regulated transcription factors, including Activating Transcrip-
tion Factor-1/2 (ATF-1/2)/cAMP-responsive Element Binding
(CREB) protein, SNAIL/SLUG, nuclear factor kappa B (NFkB),
signal transducers and activators of transcription (STAT) 3 and 5,
directly control the expression of adhesion molecules, matrix-
degrading enzymes, motility factors, cytokines, survival factors and
growth factors/receptors enabling complex interactions between
melanoma cells and the extracellular milieu during metastatic
dissemination [6,7,8,9,10,11,12,13].
Animal model studies helped demonstrate that inactivation of
AP-2a in SB2 non-metastatic primary cutaneous melanoma cells
by dominant-negative AP-2B, augmented melanoma cell tumor-
igenicity [14]. Inversely, an enforced overexpression of AP-2a in
metastatic melanoma cells inhibited tumor cell growth at
subcutaneous sites and abrogated development of melanoma lung
metastasis in vivo [15]. Importantly, we have shown through
melanoma tissue microarrays and quantitative immunofluores-
cence analysis, that AP-2a expression correlates with poor
prognosis in melanoma patients [11,16]. In many tumor types,
including melanoma, AP-2a acts as a tumor suppressor by
activating p21
Waf1/Cip1 expression and inducing cell cycle arrest
[17,18,19]. Loss of AP-2a in metastatic melanoma is directly
linked to overexpression of melanoma cell adhesion molecule
MCAM/MUC18, protease-activated receptor-1 (PAR-1), matrix
metalloproteinase-2 (MMP-2), and loss of tyrosine-kinase receptor
c-KIT [10,11,12,14,15,20].
Restoration of AP-2a in colon cancer cells reduced tumor
burden in mice and inhibited spontaneous liver metastasis by
increasing the E-cadherin/MMP-9 ratio [21]. Overexpression of
AP-2a in pancreatic cancer cells was shown to reduce tumor
growth through an altered expression pattern of cell cycle-
controlling factors such as CDK-4, CDK-6, Cyclin-G1, p27
kip1
and p57
kip2 [22]. In various cell models, AP-2a has also been
shown to regulate c-erbB-2/HER2-2/neu, plasminogen activator
inhibitor type I (PAI-1), insulin-like growth factor binding protein-
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growth factor (HGF), vascular endothelial growth factor (VEGF),
and c-Myc [23,24,25,26,27,28,29,30,31]. Despite an improved
understanding of its mechanisms of action, the cause for the loss of
AP-2a in melanoma remains unknown.
Previous studies have suggested an inverse correlation between
loss of the tumor suppressor AP-2a and upregulation of CREB
expression and activity with melanoma progression [32,33].
CREB is a member of a leucine zipper class of transcription
factors that binds to cAMP-response elements (CREs) found
within the promoter and enhancer regions of hundreds of genes
[34]. CREB is activated by a number of growth factors, hormones
and stress signals that trigger its phosphorylation at Ser133 and its
association with the co-activator paralogs CBP and p300 [35,36].
Co-activators such as TORC2, ACT and TAF4 may stabilize the
assembly of co-activator complexes over CREB target genes in
specific cell types thereby regulating CREB activity [34,35,36,37].
CREB regulates the expression of genes that suppress apoptosis,
induce cell proliferation and mediate inflammation and tumor
metastasis such as BCL-2, HER-2, IL-8 and MMP-2 [8,38,39]. In
melanoma, inactivation of CREB by dominant-negative KCREB
reduced tumor growth and experimental lung metastasis by acting
as a survival factor and regulating the expression and activity of
MMP-2 and the adhesion molecule MCAM/MUC18
[37,40,41,42]. We have demonstrated that activation of CREB
phosphorylation in melanoma is associated with constitutive
activation of the pro-inflammatory G-protein coupled receptors
PAR-1 and Platelet-Activating Factor Receptor [43]. Most
recently, we found that CREB acts as a negative regulator of the
melanoma tumor suppressor gene cysteine-rich protein 61 (CCN1/
CYR61) [7].
An overlap in the spectrum of target genes regulated by AP-2a
and CREB led us to explore the connection between the two
transcription factors. Herein, we propose a potential mechanism
by which CREB induces transcriptional repression of AP-2a
during melanoma progression through upregulation of oncogenic
E2F-1. Since AP-2a regulates key genes associated with the
acquisition of the metastatic phenotype, our observation that
CREB regulates the AP-2a expression emphasizes its role as a
‘‘master switch’’ in melanoma progression.
Results
Loss of AP-2a expression correlates with metastatic
potential of melanoma cell lines
To study the mechanism of AP-2a loss during melanoma
progression, we first examined the status of AP-2a by RT-PCR in
a panel of human melanoma cell lines exhibiting different
metastatic capabilities. Figure 1A demonstrates that AP-2a is
expressed in the non-metastatic cell lines SB2 and DX3 while both
Figure 1. Expression of AP-2a inversely correlates with melanoma metastatic potential. (A) Expression of AP-2a mRNA in human
melanoma cell lines was detected by reverse transcriptase-PCR (RT-PCR). High levels of AP-2a expression are observed in SB2 and DX3 (non-
metastatic cell lines) whereas A375SM and C8161-c9 (metastatic cell lines) show undetectable levels of AP-2a. The pcDNA3.1 AP-2a was used as a
positive control. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as a housekeeping gene. (B) Western Blot analysis of nuclear
extracts isolated from subconfluent cultures and analyzed for AP-2a protein expression. Similarly, AP-2a protein is detected in non-metastatic cell
lines. In metastatic cell lines, AP-2a expression was found to be downregulated by 99%. Lamin was used a loading control. (C) SB2 and C8161-c9 cell
lines were immunofluorescently stained for detection of AP-2a (Red). Colocalization with DAPI (Blue) and AP-2a reveal high AP-2a intensity in the
nuclei of SB2 cells while low levels of AP-2a are detected dispersed within the cytoplasm of the C8161-c9 cell.
doi:10.1371/journal.pone.0012452.g001
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express detectable levels of AP-2a mRNA. Furthermore, AP-2a
protein expression levels were determined by Western Blot.
Similarly, AP-2a was detectable in the nucleus of SB2 and DX3
whereas AP-2a was absent in both A375SM and C8161-c9
(Figure 1B).
We have previously shown that loss of nuclear AP-2a and an
increase in the cytoplasmic to nuclear AP-2a ratio correlates with
poor prognosis of melanoma patients [11,16]. To confirm if this
phenotype is recapitulated in melanoma cell lines, we examined
subcellular localization of AP-2a in cultured cell lines by
immunofluorescense. Consistent with our previous finding in
human melanoma specimens, we found that AP-2a protein is
expressed in the nuclei of non-metastatic SB2 cells but is nearly
absent in metastatic C8161-c9 cells (Figure 1C). This observation
was confirmed in a panel of 9 additional cell lines with varying
metastatic potential (data not shown).
CREB phosphorylation correlates with the metastatic
potential of melanoma cell lines and inversely correlates
with AP-2a expression
Several factors involved in melanoma invasion, resistance to
apoptosis and proliferation, such as MMP-2, MCAM/MUC18,
BCL-2 and TGF-a are regulated by both CREB and AP-2a,
albeit in an opposite manner [8,33,37]. Therefore, we tested the
hypothesis that a gain in CREB activity results in the loss of
AP-2a expression in melanoma. Analysis of CREB protein
expression by Western Blot demonstrates that while levels of
total CREB protein remain similar in all melanoma cell lines,
the levels of its phosphorylation at Serine 133 (pCREB), a
critical functional phosphorylation site, were significantly higher
(approximately 5-fold increase) in metastatic melanoma cell
lines (A375SM and C8161-c9) as compared to non-metastatic
melanoma cell lines (SB2 and DX3) (Figure 2A). Additionally,
we assessed the levels of pCREB by confocal microscopy in both
SB2 and C8161-c9. As depicted in Figure 2B, high pCREB
intensity in the nuclei of C8161-c9 cells (low AP-2a)w a s
detected whereas pCREB was mostly undetectable in the nuclei
of SB2 cells (high AP-2a), thus supporting our Western Blot
analyses.
To examine whether activation of CREB results in loss of AP-
2a expression, we inhibited CREB phosphorylation in A375SM
and C8161-c9 cells by using several kinase inhibitors such as H-89
(PKA/MSK pathway), KN-93 (CaMKIV pathway), SL0101-1
(p90RSK pathway), and Triciribine (Akt pathway). H-89 restored
the overall levels of AP-2a expression (Figure 2C), and induced
accumulation of AP-2a in the nuclei of A375SM and C8161-c9
cells (data not shown). KN-93, SL0101-1 and Triciribine inhibited
CREB phosphorylation, in a similar manner to H-89, leading to
increased expression of AP-2a (Figure S1), suggesting that
activation of CREB during metastatic progression results in loss
of AP-2a expression.
CREB acts as a negative transcriptional regulator of AP-2a
expression
To confirm that restoration of AP-2a is specific to CREB, we
stably silenced CREB expression in metastatic A375SM and
C8161-c9 cells lines using lentiviral small hairpin RNA (shRNA),
as described previously [7]. Figure 3A demonstrates that CREB
expression was reduced by 90% and 80% in A375SM and C8161-
c9 cells respectively, as compared to cells transduced with non-
targeting shRNA (NTshRNA). In line with the use of pathway
inhibitors to decrease pCREB, CREB silencing via shRNA
resulted in upregulation of AP-2a expression in both metastatic
melanoma cell lines, confirming that CREB indeed acts as a
negative regulator of AP-2a (Figure 3A).
Figure2.Inhibitionof pCREB results in increased AP-2aexpression.
(A) pCREB was analyzed in non-metastatic and metastatic cell lines by
Western Blot. As confirmed by densitometry, pCREB in metastatic cell lines
is approximately 5-fold higher as compared to non-metastatic cell lines. a-
Actin is used as a loading control. (B) SB2 and C8161-c9 cell lines were
immunofluorescently stained for detection of pCREB (Red). Colocalization
with DAPI (Blue) and pCREB reveal high pCREB intensity in the nuclei of
C8161-c9 cells (low AP-2a) while low level of pCREB is mostly undetectable in
the nuclei of SB2 cells (high AP-2a). (C) Expression of AP-2a was detected in
A375SM and C8161-c9 cell lines after incubation with the pCREB inhibitor, H-
89. Complete restoration of AP-2a expression was observed in both cell lines
after treatment with H-89 at 10 mM. Lamin was used as a loading control.
doi:10.1371/journal.pone.0012452.g002
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2a gene (GenBank Accession Number NM_003220.2). AP-2a
promoter analysis for consensus transcription factor binding motifs
using Genomatix software revealed the presence of three
previously unidentified, putative CRE-like sites at positions
21,450 bp (ACTTAAAA), 21,132 bp (ACACGTCT) and
Figure 3. Silencing CREB increases AP-2a expression and promoter activity. (A) Western Blot analysis showing silencing of CREB in both
A375SM and C8161-c9 cells stably transduced with CREB shRNA as compared to non-targeting control (NTshRNA). Approximately 80–90% CREB
downregulation was observed in the CREB shRNA transduced cells as compared to NTshRNA as determined by densitometry. Following silencing of
CREB, expression levels of AP-2a were upregulated in both A375SM and C8161-c9 cell lines as detected by Western Blot. a-Actin was used as a loading
control for total lysate samples. Lamin is used as a loading control for nuclear fractions. (B) The AP-2a promoter region (nucleotides 21,500 to +50 from
the transcription initiation site) was amplified from genomic DNA and cloned into the pGL3-basic firefly luciferase vector. Schematic representation of
the promoter region shows the predicted CREB and E2F-1 binding sites. The luciferase activity driven by the AP-2a promoter was significantly increased
by 90- and 20-fold after CREB silencing in both A375SM and C8161-c9 cell lines respectively, as compared to NT transduced cells. *, p,0.001. SB2 cells
were used as a positive control. (C) Rescue of CREB expression in CREB-silenced cells resulted in down-regulation of AP-2a expression. a-Actin was used
as a loading control. (D) Theluciferase activity driven by the AP-2a promoter decreased significantly (*, p,0.001) after rescue of CREB expression in both
A375SM and C8161-c9 cell lines. NTshRNA/EV, nontargeting control cells. CREBshRNA/EV, CREB-silenced control cells. CREBshRNA/RESCUED, CREB-
silenced cells transduced with CREB nontargetable expression vector. (E) Chromatin Immunoprecipitation (ChIP) studies showed decreased binding of
CREB to the promoter of AP-2a in both CREB-silenced cell lines (A375SM and C8161-c9) as compared to NT transduced cell lines. IgG antibodies were
used as negative controls. Input DNA was used to determine equal amounts of chromatin. (F) Colony formation assay performed in soft agar layer
depicts a significant decrease in clonogenicity after silencing CREB in both A375SM and C8161-c9. *, p,0.001.
doi:10.1371/journal.pone.0012452.g003
CREB Inhibits AP2a in Melanoma
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e124522962 bp (AAGTAACC) of the proximal AP-2a promoter region
(Figure 3B - Schematic representation). In addition, we also found
one binding site for oncogenic transcription factor E2F-1 at
position -685bp (GGGCCAAA) of the proximal AP-2a promoter
(Figure 3B). To confirm that CREB regulates AP-2a expression at
the transcriptional level, we cloned the AP-2a promoter in front of
a luciferase reporter gene. Reflecting the pattern of AP-2a mRNA
expression (Figure 1A), AP-2a promoter activity was significantly
higher in non-metastatic SB2 cells as compared to metastatic
A375SM and C8161-c9 cells transduced with NTshRNA
(Figure 3B). The luciferase activity driven by the AP-2a promoter
increased after CREB silencing by 90-fold (p,0.001) in A375SM
and by 20-fold (p,0.001) in C8161-c9 cells as compared to the
activity in NTshRNA control cells (Figure 3B).
To further establish the link between CREB and AP-2a
expression, we next rescued CREB expression in both CREB-
silenced cell lines by overexpressing CREB in which silent
mutations were introduced to render it nontargetable to CREB
shRNA (Figure 3C). Western Blot analysis of these cells
demonstrated that CREB rescue resulted in restoration of CREB
expression to levels comparable to those in control cells
(NTshRNA/EV). Restoring CREB expression in these cells also
resulted in decreased AP-2a expression (Figure 3C) and decreased
luciferase activity driven by the AP-2a promoter (Figure 3D).
Moreover, we sought to confirm that inhibition of AP-2a was
dependent on CREB phosphorylation. To that end, we created a
missense mutation at position 133 (S R A), the main phosphor-
ylation site of CREB [34], in the nontargetable expression vector
(CREB(S133A)). Western Blot analysis of these cells revealed that
CREB(S133A) expression vector rescued the total level of CREB.
However, this mutant was not able to decrease the AP-2a
expression in either of the CREB-silenced cell lines (Figure S2).
To confirm that CREB binds to the AP-2a promoter, we next
utilized Chromatin Immunoprecipitation (ChIP) with primers
designed to amplify the AP-2a gene 59 flanking sequence that
contains 3 putative CRE-like binding sites (Figure 3E). We found
that CREB directly associates with AP-2a promoter in A375SM
and C8161-c9 NTshRNA cells. This binding was significantly
decreased after CREB silencing in both cell lines (Figure 3E).
Additionally, both CREB and AP-2a have been shown to
regulate expression of genes involved in cell proliferation [8]. We
have previously demonstrated that overexpression of AP-2a in
colon cancer cells reduces their ability to form colonies in agar
[21]. Therefore, in order to understand the contribution of CREB
to melanoma growth and metastasis, we next assessed the effect of
CREB silencing on the clonogenicity of metastatic melanoma cells.
As seen in Figure 3F, both A375SM and C8161-c9 stably
transduced with CREB shRNA had a significant decrease in size
and number of colonies after 25 days as compared to NTshRNA
cells. The mean number of colonies decreased significantly by
62% in A375SM cells (p,0.001), and by 49% in C8161-c9 cells,
(p,0.001). Taken together, our data suggest that CREB regulates
AP-2a transcription in melanoma cells via direct binding to its
promoter, thus repressing AP-2a expression and its tumor
suppressor role.
E2F-1 acts as a negative regulator of AP-2a promoter
activity and expression downstream of CREB
We have previously subjected CREB-silenced A375SM cells to
cDNA microarray analyses in order to identify downstream target
genes regulated by CREB in melanoma [7]. cDNA microarray
experiments have indicated that E2F-1 is one of the genes whose
expression was decreased by CREB silencing. Since multiple E2F-
1 binding sites are present on the promoter of AP-2a,w e
investigated the hypothesis that E2F-1 acts downstream of CREB
and that together, CREB and E2F-1 regulate AP-2a expression.
Indeed, CREB silencing led to decreased E2F-1 protein expression
in both cell lines by 60% (A375SM) and 80% (C8161-c9), thus
confirming our cDNA microarray findings (Figure 4A).
To assess the status of E2F-1 during melanoma progression, we
performed Western Blot analysis in non-metastatic and metastatic
melanoma cell lines. As shown in Figure 4B, E2F-1 was found to
be upregulated in A375SM and C8161-c9 as compared to non-
metastatic cell lines, SB2 and DX3. To investigate whether E2F-1
contributes to regulation of AP-2a expression, we transiently
transfected E2F-1 into an AP-2a-positive SB2 cell line. E2F-1
overexpression resulted in significant downregulation of AP-2a
protein expression by 90% in SB2 cells (Figure 4C). As expected,
overexpression of E2F-1 in AP-2a-negative A375SM cells did not
affect AP-2a levels (data not shown). Loss of AP-2a protein in SB2
cells was further paralleled by a significant, 4-fold decrease in AP-
2a promoter activity upon overexpression of E2F-1 (Figure 4D,
p,0.001).
To confirm that E2F-1 regulates AP-2a transcription via direct
binding to its promoter, we conducted another series of ChIP
experiments using ChIP primers situated close to the E2F-1
binding site. We found that in metastatic melanoma cells, E2F-1
actively binds the AP-2a promoter. Furthermore, CREB silencing
inhibited E2F-1 binding to the AP-2a promoter in both A375SM
and C8161-c9 cells (Figure 4E).
Finally, to verify that the CREB-like sites as well as the E2F-1
site within the AP-2a promoter were involved in the regulation of
AP-2a transcription, we altered each binding site by introducing
point mutations. Mutation of a CREB element at position -962
and a E2F-1 element at position -685 (Figure 4F) led to a
significant increase in the AP-2a promoter-driven reporter activity
in both A375SM and C8161-c9 parental cells (Figure 4F).
Interestingly, when analyzing CREB-like sites at position –1450
and –1132, no significant differences in the reporter activity were
found (Figure 4F). Overall, these site-directed mutation analyses
revealed that the CREB site located at -962 and the E2F-1 site
located at 2685 within the AP-2a promoter region, are essential
for regulating AP-2a transcription.
Taken together, our results suggest that CREB regulates AP-2a
expression via two pathways: 1) by directly binding the AP-2a
promoter and repressing its activity, and 2) by stimulating
expression of E2F-1, which also binds to AP-2a promoter and
represses its activity.
Increase in AP-2a restores the non-metastatic phenotype
of melanoma by regulating p21
Waf1 and MCAM/MUC18
Since AP-2a regulates several genes involved in the progression
of human melanoma [12,15,33], we sought to determine if re-
expression of AP-2a after CREB silencing reverts the expression of
AP-2a downstream target genes.
It has been previously shown that forced expression of AP-2a
resulted in a transient transcriptional upregulation of p21
Waf1
expression and concomitant cell cycle arrest [19]. Furthermore, we
have shown that upregulation of MCAM/MUC18 expression in
metastatic cells correlates with loss of expression of AP-2a. Indeed,
we have also shown that AP-2a regulates MCAM/MUC18
expression through direct binding to its promoter, suppressing
tumorigenicity and metastatic potential of human melanoma cells
[12].
Figure 5A demonstrates that p21
Waf1 is expressed in the non-
metastatic SB2 and DX3 cell lines but it is downregulated in the
metastatic melanoma cell lines A375SM and C8161-c9. Additio-
naly, the CREB-silenced A375SM and C8161-c9 cell lines
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PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12452Figure 4. E2F-1 regulates AP-2a transcription by direct binding to the AP-2a promoter. (A) Western Blot analysis showing downregulation
of E2F-1 in both CREB-silenced A375SM and C8161-c9 cells by 60% and 80% respectively, as compared to non-targeting control (NTshRNA). Actin is
used as a loading control. (B) E2F-1 expression was analyzed by Western Blot in SB2, DX3 (low metastatic), A375SM and C8161-c9 (highly metastatic)
total cell extracts. Lower expression of E2F-1 is detected in non-metastatic cell lines while in metastatic cell lines, E2F-1 is upregulated. Actin was used
a loading control. (C) Transient expression of E2F-1 significantly decreased AP-2a protein levels in SB2 cells by 90%. (D) The luciferase activity driven
by the AP-2a promoter was significantly decreased after transient expression of E2F-1 in the SB2 cell line (high AP-2a, low E2F-1 expression) as
compared with pcDNA3.1 alone. *, p,0.001. (E) Chromatin Immunoprecipitation (ChIP) assays showed decreased binding of E2F-1 to the AP-2a
promoter in both CREB-silenced cell lines (A375SM and C8161-c9) as compared to NT transduced cell lines. IgG antibodies were used as negative
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Waf1 expression by 9- and 3-fold
respectively, as compared to cells transduced with NT shRNA
(Figure 5B). On the other hand, MCAM/MUC18, which has
been shown to be upregulated in metastatic melanoma cell lines
[43,44,45], was found to be significantly downregulated by 90% in
both cell lines after CREB silencing (Figure 5C).
Altogether, these experiments uncover the link between AP-2a
and CREB, thereby establishing a new molecular mechanism by
which CREB induces transcriptional repression of AP-2a via
upregulation of E2F-1. These studies provide yet another
mechanism by which CREB contributes to the acquisition of the
malignant phenotype in human melanoma.
Discussion
Melanoma progression is associated with several molecular
changes including CCN1/CYR61, MCAM/MUC18 and PAR-1
[7,8,44,46]. We have shown that one of the major switches related
with melanoma progression is the loss of expression of the
transcription factor AP-2a [15]. However, the molecular mech-
anism by which AP-2a is downregulated during melanogenesis has
not been elucidated.
In the early 80s and mid 90s, several studies showed that the
lack of expression or downregulation in AP-2a in malignant
melanoma cells could be explained through a deletion of the distal
portion of the long arm of chromosome 6 [47,48,49] or with
abnormalities in the short arm of chromosome 6 (6p), near the
HLA locus to which the AP-2a gene is mapped [48,50]. Although,
re-introduction of chromosome 6 into metastatic melanoma cells
inhibits their tumorigenicity and metastatic potential [51,52,53],
the status of AP-2a was not clarified. Thus, we previously showed
by quantitative analysis of melanoma tissue microarrays, that the
loss of nuclear AP-2a expression was associated with malignant
transformation and progression of melanoma and that high
cytoplasmic to nuclear ratio of AP-2a correlates with poor
prognosis [11,16]. Corroborating the tissue microarray data, our
current study further reveals an inverse correlation between AP-2a
expression and the metastatic potential of melanoma cell lines
[11,16,54].
AP-2a plays a pivotal role in regulating the expression of several
genes involved in cell proliferation (HER2), cycle regulation
(p21
Waf1), apoptosis (c-KIT, Bcl-2, FAS/APO-1), adhesion (E-
cadherin), and invasion/angiogenesis (MMP-2, VEGF) [8,15,33].
Recently, overexpression of AP-2a in pancreatic cancer cells was
shown to reduce tumor growth through an altered expression
pattern of cell cycle-controlling factors such as CDK-4, CDK-6,
cyclin-G1, p27
kip1 and p57
kip2 [22]. Additionally, some of the genes
regulated by AP-2a in melanoma, such as MCAM/MUC18 and
MMP-2,arealsoregulatedbytheCREB transcriptionfactor[8,37].
Interestingly, we demonstrated that AP-2a is downregulated with a
concomitant increase in CREB expression during melanoma
progression [55]. With that in mind, we have shown that
inactivation of AP-2a by a dominant-negative AP-2a (AP-2B) in
SB2 non-metastatic cells increased cell tumorigenicity in nude mice
[14]. Moreover, overexpression of AP-2a in metastatic melanoma
cells reduced tumor growth and experimental lung metastasis
through downregulation of the above described factors [20].
In our current study, inhibition of p-CREB by H-89
significantly restored the levels of AP-2a as well as its translocation
to the nucleus, thus leading us to hypothesize that CREB is
involved in the regulation of AP-2a in melanoma. To study the
mechanism by which CREB regulates AP-2a expression, we stably
transduced metastatic melanoma cell lines with shRNA targeting
CREB. Similar to treatment with H-89, silencing CREB led to
significant upregulation of AP-2a expression. In addition, the
activity of the luciferase reporter gene driven by the AP-2a
promoter (21,500 bp to +50 bp) was increased after CREB
silencing. Previous work has shown that the promoter of AP-2a
does not contain any canonical sequence motifs for basal
transcription factors, such as TATA-, CCAAT or SP-1 boxes
[56]. Moreover, initiation of transcription occurs just upstream of
a long TC-rich region between residues 2240 and 2100. Further
analyses also showed that the promoter of the AP-2a gene is
subject to positive autoregulation by its own gene product [56].
Furthermore, our analyses of the AP-2a promoter revealed
putative consensus binding sites for CREB and E2F-1 transcrip-
tion factors.
Herein we demonstrate that the expression levels of E2F-1 were
also downregulated after CREB silencing in both A375SM and
C8161-c9 cell lines. However, it had not been described whether
CREB regulates E2F-1 expression at the transcriptional level
during melanoma progression. The E2F transcription-factor
family is inextricably linked with cell-cycle control and apoptosis.
E2F coordinates a large group of genes involved in regulating the
G1-to S-phase transition, as well as other genes involved in
controls. Input DNA was used to determine equal amounts of chromatin. (F) A schematic representation of the promoter point mutations is depicted
on the left side of the panel. The three identified CRE-like binding sites as well as the E2F-1 biding site were mutated, as described in ‘‘Material and
Methods’’. Mutation of one CREB-like binding site (2962) as well as the E2F-1 binding site, led to a significant increase in the AP-2a promoter activity
in both the A375SM and C8161-c9 parental cells. *p,,0.01.
doi:10.1371/journal.pone.0012452.g004
Figure 5. Upregulation of AP-2a in metastatic melanoma after
CREB silencing modulates p21
Waf1 and MCAM/MUC18 expres-
sion. (A) Expression of p21
Waf1 in a panel of melanoma cell lines with
different metastatic potential. (B) p21
Waf1 expression was upregulated
in the two CREB-silenced A375SM and C8161-c9 cell lines. (C) MCAM/
MUC18 was downregulated by 90% in both A375SM and C8161-c9 cell
lines following CREB silencing. Actin was used as a loading control.
doi:10.1371/journal.pone.0012452.g005
CREB Inhibits AP2a in Melanoma
PLoS ONE | www.plosone.org 7 August 2010 | Volume 5 | Issue 8 | e12452apoptosis [57,58,59]. Conversely, studies on the well characterized
E2F-1 have indicated that it may have characteristics of both an
oncogene, by promoting the proliferation of cells beyond their
normal constraints, and as a tumor suppressor [60,61,62,63].
Recently, silencing E2F-1 effectively inhibited gastric cancer
progression by reducing cell proliferation and increasing apoptosis
[64] suggesting an oncogenic function.
Our ChIP analyses provide additional mechanistic evidence
that CREB and E2F-1 negatively affect AP-2a transcription by
binding to and inhibiting the activity of its promoter. In fact,
forced expression of E2F-1 in SB2 cells decreased the expression of
AP-2a as well as the luciferase activity driven by the AP-2a
promoter. This data suggests that E2F-1 itself can suppress AP-2a
transcription thereby uncovering a new potent target for
melanoma therapy.
Finally, we confirmed that the upregulation of AP-2a after
CREB silencing was functional and could modulate the expression
of p21
Waf1 and MCAM/MUC18. AP-2a has been previously
shown to activate p21
Waf1 leading to inhibition of cellular DNA
synthesis and stable colony formation in colon carcinoma cells
[17]. Moreover, significant correlation between AP-2a expression
and p21
Waf1 levels have been reported in breast cancer and stage I
cutaneous malignant melanoma [65,66]. We have previously
shown that the level of expression of MCAM/MUC18 in
melanoma directly correlates with tumor progression and the
acquisition of metastatic potential as it is transcriptionaly regulated
by both AP-2a and CREB [12]. Our data show a significant
upregulation in p21
Waf1 expression along with decreased MCAM/
MUC18 expression following CREB silencing and AP-2a
expression thereby confirming functional modulation of AP-2a
by CREB.
Taken together, we provide a novel molecular mechanism by
which oncongenic transcription factors, CREB and E2F-1,
contribute to the metastatic phenotype of melanoma by negatively
regulating AP-2a expression at the transcriptional level.
Materials and Methods
Cell lines, culture conditions and treatment
All the cell lines used in this study are established cell lines. The
A375SM human melanoma cell line [67] was previously
established from pooled lung metastases produced by A375-P
cells injected i.v. into nude mice and maintained in Eagle’s MEM
supplemented with 10% fetal bovine serum (FBS), as previously
described [20]. Both non-metastatic cell lines, SB2 [68] and DX3
[69], were maintained in Eagle’s MEM supplemented with 10%
FBS. The amelanotic C8161-c9 aggressive human melanoma cell
line [70] was maintained in DMEM-F12 supplemented with 5%
FBS. The 293FT cells (Invitrogen), used to produce lentiviral
shRNA were maintained in DMEM supplemented with 10% FBS,
according to the manufacturer’s instructions. For experiments
utilizing H-89 (Calbiochem), KN-93 (Sigma-Aldrich), SL0101-1
(TOCRIS Bioscience) or Triciribine (Sigma-Aldrich) inhibitors,
the cells were deprived of serum for 24 h and then treated with
IC50 of 10 mM, 0.5 mM, 1 mM and 10 mM respectively, for 24 h.
Lentiviral shRNA to CREB
CREB shRNA (target sequence: 59-GAGAGAGGTCCGTC-
TAATG-39) and a non-targeting shRNA (target sequence: 59-
UUCUCCGAACGUGUCACGU-39) were obtained as previously
described [7]. Metastatic melanoma A375SM and C8161-c9 cell
lines plated at 70% confluency in six-well plates were transduced
with the virus. After 16 hours, the virus-containing medium was
removed and replaced with normal growth medium [7].
Nontargetable CREB Expression Vector
The lentiviral nontargetable CREB expression vector was
created as described elsewhere [7]. To rescue CREB expression
in stably CREB-silenced cells, A375SM and C8161-c9 CREB-
shRNA or NT-shRNA were plated in 6-well plates and transduced
with the virus containing either the nontargetable CREB
expression vector or empty vector. After 48 h, the cells were
replated and selected as described previously [7]. The CREB
expression was confirmed by Western Blot.
Western Blot analysis
CREB, pCREB, E2F-1 and p21
Waf1 were detected in total cell
extracts (20 mg) while AP-2a was detected in the nuclear fraction
(20 mg) by 10% SDS-polyacrylamide gel electrophoresis and
transferred to Immobilon P transfer membrane (Millipore). The
membranes were washed in Tris-buffered saline with Tween
(10 mM Tris-HCl, pH 8, 150 mM NaCl, and 0.05% Tween 20)
and blocked overnight at 4uC with 5% nonfat milk in Tris-buffered
saline with Tween. The blots were then probed overnight at 4uC
with primary antibodies at 1:2000 (anti-CREB, Cell Signaling),
1:2000 (anti-pCREB Cell Signaling), 1:2000 (anti-E2F-1, Santa
Cruz), 1:2000 (anti-p21, Cell Signaling) and 1:2000 (anti-AP-2a,
Santa Cruz). After 2 h of incubation with horseradish peroxide-
conjugated secondary antibody, immunoreactive proteins were
detected by enhanced chemiluminescence per the manufacturer’s
instructions (ECL detection system; Amersham Biosciences). For
AP-2a in the nuclear extract, A375SM and C8161-c9 were
prepared according to the manufacturer’s instructions (Nuclear
Extraction Kit, Panomics). Protein concentrations were determined
by using the Bradford protein assay (Bio-Rad).
Expression vector constructs
The total RNA was extracted from A375SM and reverse-
transcripted (RT) using a commercial kit (Clontech). The
pcDNA3.1 for AP-2a was obtained as previously described [10].
The ORF of E2F-1 was PCR-amplified from the RT product with
the following two primers: E2F-1-Nhe-F: 59-CTAGCTAG-
CATGGCCTTGGCCGGGGCCCCTGC-39 and E2F-1-R: 59-
TCAGAAATCCAGGGGGGTGAGGTCC-39. The pcDNA3.1
for nontargetable CREB expression vector was obtained as
previously descibed [7]. To create CREB expression vector
containing a missense mutation at position 133 (S R A,
CREB(S133A)), we utilized the following two primers: CreB-
S133A-F 59- CTTTCAAGGAGGCCTGCCTACAGGAAAAT-
TTTG-39 and CreB-S133A-R 59-CAAAATTTTCCTGTAGG-
CAGGCCTCCTTGAAAG-39. The PCR products were digested
with NheI and cloned into pcDNA3.1 through the same restriction
enzyme site. The inserted ORF was confirmed by sequencing.
Transient transfections were performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions. As a
control, cells were transduced with empty vector pcDNA3.1.
Reporter constructs and luciferase activity assays
The AP-2a promoter region (nucleotides 21,500 to +50 from the
transcription initiation site) was amplified from A375SM cell
genomic DNA and ligated into the pGL3-basic vector (Promega).
Analysis of transcription factor binding sites was performed using
GENOMATIX software (http://www.genomatix.de). Site-directed
mutageneses of the CRE sites as well as E2F-1 binding site were
performed using the QuikChange II XL Site-Directed Mutagenesis
Kit (Stratagene) accordingto manufacturer’s instructions.Transient
transfections were performed as previously described [7]. Briefly, a
total of 2.5610
4 cells/well in a 24-well plate were transfected with
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enhancer sequence or with 0.8 mg of the pGL3-AP-2a firefly
luciferase expression constructs. For each transfection, 2.5 ng of
cytomegalovirus (CMV)-driven renilla luciferase reporter construct
(pRL-CMV, Promega) was included. After 4 hours, the transfection
mediumwasreplaced with serum-containinggrowth medium.After
48 hours, the cells were harvested and subjected to lysis, and the
luciferase activity was assayed utilizing a Dual Luciferase Reporter
Assay System (Promega) according to the manufacturer’s instruc-
tions. The luciferase luminescence (relative light intensity610
6)w a s
measured with the LUMIstar reader (BMG Labtech). The ratio of
firefly luciferase activity to CMV-driven renilla luciferase activity
was used to normalize for differences in transfection efficiency
among samples.
Chromatin Immunoprecipitation assay (ChIP)
ChIP assays were performed utilizing the ChIP-IT Express kit
from Active Motif according to the manufacturer’s protocol.
Briefly, cells were fixed with 1% formaldehyde. The cross-linking
reaction was stopped with 0.125 M glycine. The cells were pelleted
and resuspended in a hypotonic buffer, and cell nuclei were
isolated by using a Dounce homogenizer. The chromatin was then
sheared into small fragments by adding an enzymatic solution for
10 minutes at 37uC. Fractions of chromatin solutions were
incubated overnight at 4uC with either 3 mg of anti-CREB, anti-
E2F-1 or IgG control antibodies crosslinked to magnetic beads.
The immune complexes were then eluted from the magnetic
beads, and proteins were reverse-crosslinked at 65uC for
2.5 hours. Proteins were digested with 2 ml of Proteinase K at
37uC for 1 hour, extracted in elution buffer, and analyzed by
PCR. A 609-bp fragment spanning the 21559 to 2850 region of
the AP-2a promoter was amplified by PCR using primer
sequences forward 59-GCTCAGCCAGGAAAATTAATTACT-
CTG-39 and reverse 59-CAGGTTGGAGATTCTGCCAAGC-
GGCTC-39. Another fragment of 135-bp spanning the 2743 to
2549 region of the AP-2a promoter was also amplified by PCR
using primer sequences forward and 59-GGTGGTTATGTT-
TAATTGCGAAAGG-39 and reverse 59-GGCATCTCTGGA-
GAAAAGGAAGC-39.
Semiquantitative reverse transcriptase-PCR
One microgram of total RNA was reverse primed with an oligo
(dT) primer and extended with Moloney murine leukemia virus
reverse transcriptase (Clontech). The PCR was performed using
the Clontech Advantage cDNA PCR kit in a 50 ml reaction
mixture containing 1x PCR buffer, 5 ml cDNA, 0.2 mmol/L
deoxynucleotide triphosphate, and 2.5 units of Taq polymerase.
For AP-2a quantification, specific primers (59-CTGCCAACGT-
TACCCTGC-39 and 59-TAGTTCTGCAGGGCCGTG-39) were
used. Glyceraldehyde-3-phosphate dehydrogenase cDNAs were
amplified by PCR in the same reaction mixture and carried out by
an initial denaturation for 2 min at 94uC, followed by 27 cycles of
denaturation at 94uC for 1 min, annealing at 58uC for 1 min, and
extension at 72uC for 1 min, with a final elongation step at 72uC
for 5 min. A final elongation step was carried out at 72uC for
10 min.
Confocal microscopy
Cells (2610
3cells) were cultivated on round glass coverslips
(13 mm) for 24 h following fixation with 3.7% paraformaldehyde
for 15 min at room temperature. Cells were then incubated with
block solution (150 mM NaCl (Merck), 50 mM Tris (Gibco
Invitrogen, Carlsbad, CA), 0.25% BSA (Sigma), and 0.5% Tween
20 (Sigma), pH 7.2) for 1 hour at room temperature. Anti-AP-2a
antibody (5 mg/ml, Santa Cruz) or anti-pCREB antibody (1 mg/
ml, Cell Signaling) were incubated for 12 h at 4uC. After several
washes in PBS, anti-mouse IgG rhodamine conjugate (1:500,
Sigma) was incubated at room temperature for 1 h. Alternatively,
prior to fixation, cells were treated with H-89 (10 mM) for 30 min
at 37uC. Staining of nuclei was performed with 50 mg/ml DAPI
(Invitrogen) for 1 h at room temperature. The coverslips were
treated with a mounting medium (Vectashield; Vector Laborato-
ries, Burlingame, CA) to reduce bleaching and were examined by
laser scanning fluorescence confocal microscope (MRC 1024/UV
System; Bio-Rad, Hercules, CA) equipped with a transmitted light
detector for Nomarski differential interference contrast.
Soft-Agar colony formation assay
Base layers (2 ml) of Eagle’s medium (MEM) supplemented with
20% FBS containing 0.6% seaplaque agarose were set in 6-well
plates. This was overlaid with 1 ml of a second layer of 0.8% agar
containing a suspension of 5610
3 cells/well. All cultures were
done in triplicate. Colonies were scored after incubation at 37uC
for 25 days.
Statistical analysis
Significance was determined by a two-tailed Student’s t test. p
values ,0.05 were considered statistically significant.
Supporting Information
Figure S1 Inhibition of pCREB results in increased AP-2a
expression. Expression of AP-2a was detected in A375SM and
C8161-c9 cell lines after incubation with the CaMKIV inhibitor
(KN-93), p90RSK inhibitor (SL 0101-1), and AKT inihibitor
(Triciribine). Increased AP-2a expression was observed in both cell
lines after treatment with each pathway inhibitor. Lamin was used
as a loading control.
Found at: doi:10.1371/journal.pone.0012452.s001 (0.38 MB TIF)
Figure S2 Inhibition of AP-2a is dependent on pCREB.
Transient expression of nontargetable CREB carrying a substitute
mutation (S133A) in CREB-silenced cells does not inhibit AP-2a
expression in either A375SM or C8161-c9 cell lines. Lamin was
used as a loading control.
Found at: doi:10.1371/journal.pone.0012452.s002 (0.39 MB TIF)
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